| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/14/2023 | 79.28% | Wedbush | $4 → $1 | Downgrades | Outperform → Neutral |
| 08/11/2023 | 79.28% | Stifel | $4 → $1 | Downgrades | Buy → Hold |
| 08/11/2023 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 06/05/2023 | 4381.89% | HC Wainwright & Co. | → $25 | Reiterates | Buy → Buy |
| 05/11/2023 | 617.1% | Stifel | $5 → $4 | Maintains | Buy |
| 05/11/2023 | 4381.89% | HC Wainwright & Co. | → $25 | Reiterates | Buy → Buy |
| 03/30/2023 | 617.1% | Wedbush | → $4 | Reiterates | → Outperform |
| 03/30/2023 | 1692.76% | EF Hutton | → $10 | Reiterates | → Buy |
| 03/30/2023 | 4381.89% | HC Wainwright & Co. | → $25 | Reiterates | → Buy |
| 03/30/2023 | 168.91% | Evercore ISI Group | $2 → $1.5 | Downgrades | Outperform → In-Line |
| 02/07/2023 | 4381.89% | HC Wainwright & Co. | → $25 | Reiterates | → Buy |
| 01/05/2023 | 1692.76% | EF Hutton | → $10 | Initiates Coverage On | → Buy |
| 11/15/2022 | 617.1% | Wedbush | $12 → $4 | Maintains | Outperform |
| 03/04/2022 | 2409.86% | Stifel | $17 → $14 | Maintains | Buy |
| 02/08/2021 | 5278.27% | Jefferies | → $30 | Initiates Coverage On | → Buy |
| 08/12/2020 | 4381.89% | HC Wainwright & Co. | $30 → $25 | Maintains | Buy |
| 04/22/2020 | 5278.27% | HC Wainwright & Co. | → $30 | Initiates Coverage On | → Buy |
| 04/22/2020 | 4740.44% | Wedbush | → $27 | Initiates Coverage On | → Outperform |
| 04/16/2020 | 5278.27% | Baird | → $30 | Initiates Coverage On | → Outperform |
| 09/04/2019 | 5278.27% | Roth Capital | → $30 | Initiates Coverage On | → Buy |
| 07/15/2019 | — | Evercore ISI Group | Initiates Coverage On | → Outperform | |
| 07/15/2019 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 07/15/2019 | 4023.34% | Canaccord Genuity | → $23 | Initiates Coverage On | → Buy |
| 07/15/2019 | 4919.72% | Stifel | → $28 | Initiates Coverage On | → Buy |
What is the target price for Atreca (BCEL)?
The latest price target for Atreca (NASDAQ: BCEL) was reported by Wedbush on August 14, 2023. The analyst firm set a price target for $1.00 expecting BCEL to rise to within 12 months (a possible 79.28% upside). 13 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Atreca (BCEL)?
The latest analyst rating for Atreca (NASDAQ: BCEL) was provided by Wedbush, and Atreca downgraded their neutral rating.
When is the next analyst rating going to be posted or updated for Atreca (BCEL)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Atreca, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Atreca was filed on August 14, 2023 so you should expect the next rating to be made available sometime around August 14, 2024.
Is the Analyst Rating Atreca (BCEL) correct?
While ratings are subjective and will change, the latest Atreca (BCEL) rating was a downgraded with a price target of $4.00 to $1.00. The current price Atreca (BCEL) is trading at is $0.56, which is out of the analyst's predicted range.